RecruitingPhase 4NCT06917664
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Sponsor
China National Center for Cardiovascular Diseases
Enrollment
220 participants
Start Date
Jun 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Fully informed and voluntarily signed informed consent;
- Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )
Exclusion Criteria1
- Symptomatic hypotension and/or a SBP < 100 mmHg at screening; 2.Estimated GFR < 30 mL/min/1.73m2; 3.Serum potassium > 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGsacubitril/valsartan
Sacubitril/valsartan therapy after isolated CABG
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06917664
Related Trials
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT067368998 locations
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
NCT067102101 location
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT0542737043 locations
Scaffold in Emilia Romagna and in the MAGIC Network
NCT0332796117 locations
S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System
NCT034439997 locations